论文部分内容阅读
1990年我们曾经报道卡铂的Ⅱ期临床试验结果。自199i年10月至1992年10月,卡铂临床协作组共十二间医院继续应用德州制药厂生产的卡铂单药治疗或联合其它抗癌药物治疗各类恶性肿瘤共529例,单药治疗总有效率26.5％,联合化疗总有效率_45％,主要毒性反应为轻度或中度的骨髓抑制和胃肠道反应,患者一般均可耐受。本组治疗结果再次表明卡铂是一种有效低毒广谱的新抗癌药。
In 1990 we reported the results of phase II clinical trials of carboplatin. From October 199i to October 1992, a total of 529 cases of malignant tumors were treated with carboplatin monotherapy or combined with other anticancer drugs in 12 hospitals of the Carboplatin Clinical Collaborative Group. The total effective rate of treatment was 26.5%, and the total effective rate of combined chemotherapy was _45%. The main toxicity was mild or moderate myelosuppression and gastrointestinal reactions, and patients were generally tolerable. The treatment results in this group showed once again that carboplatin is a new broad spectrum anticancer drug with low toxicity.